Compare Abeona Therapeutics Inc (ABEO) vs NIO Inc. (NIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs NIO Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while NIO Inc. trades at $4.93 (market cap $12.57B). The key difference: NIO Inc. is far larger — about 33.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | NIO | |
|---|---|---|
Market Cap | $373.32M | $12.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $7.89 |
52-Week Low | $4.17 | $3.48 |
Enterprise Value | $228.22M | $11.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NIO trades at $4.88, up 1.88% with bearish technical signals despite strong delivery growth. The company shows improving fundamentals with revenue reaching $87.49B in 2025 and narrowing losses, though negative profitability metrics persist. Recent June deliveries surged 62.9% year-over-year, supporting margin expansion expectations. Analyst sentiment remains mixed with 50% buy ratings amid ongoing cash burn concerns.
NIO presents a high-risk turnaround opportunity with accelerating delivery growth and improving margins, but substantial losses and negative cash flow require careful monitoring. The stock faces technical resistance near $5 while benefiting from EV sector momentum and premium positioning in China's competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
